ClinicalTrials.gg
CompletedNCT04616430CREMEUpdated Jul 12, 2021Results posted

Topical Endoxifen in Women

A Phase 2 interventional study of Topical endoxifen and Placebo in Mammographic Breast Density, sponsored by Atossa Therapeutics, Inc.. Completed at 1 site in Sweden. Open to female participants aged 40 Years to 74 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2021-07-12.

Sponsored by Atossa Therapeutics, Inc. · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Registered 2 years 6 months after the study started (first participant enrolled Apr 2018, registered Oct 2020).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
90
Allocation
Randomized
Ages
40 Years to 74 Years
Sex
Female
01

Study summary

Karma CREME-1 consisted of 90 participants from the Karma Cohort. The major focus of the pilot trial was to estimate time to mammographic density change. The primary objective was to determine the effect size of the breast density change between topical placebo and two doses of topical endoxifen.

02

Conditions studied

  • Mammographic Breast Density
03

In context

Lead sponsor

Atossa Therapeutics, Inc. is the lead sponsor of 9 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
40 Years to 74 Years
Sexes eligible
Female
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participant in the Karma Cohort
  • Attending the national mammography screening program, i.e., aged 40-74 and have performed a screening mammogram maximum 3 months prior to study inclusion
  • Mammographic density \~4.5 % density (volumetric) measured by Volpara, at the screening mammogram performed in connection to baseline (maximum 3 months prior to inclusion). The threshold value of 4.5% corresponds to the clinical Bl-RADS score A
  • , defined as no period of menstruation during last 12 months independent of any hormonal treatment
  • must be signed before any study specific assessments are performed

Exclusion criteria

Exclusion Criteria:

  • Any previous or current diagnosis of breast cancer (including carcinoma in situ).
  • Any previous diagnosis of cancer with the exception of non-melanoma skin cancer and in situ cancer of the cervix.
  • A history of major surgery of the breast, e.g., reduction or enlargement, which might affect density measurements.
  • Mammographic Bl-RADS code 3, or above, at baseline mammography, or at mammography during time of treatment. Recall for additional examinations due to technical problems with the mammogram is accepted.
  • Currently using estrogen and progesterone based hormone replacement therapy (oral or patches). Local estrogen treatment is accepted (ex. Vagifem).
  • Non-medical approved drugs against hot-flashes including phytoestrogen.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
90 participants (actual)

Study arms

  • Placebo comparator
    Control

    Topical Placebo:Transcutol™ (2-(2-Ethoxyethoxy)ethanol); isopropanol, Crodamol™ GTCC (a fully saturated emollient triester) and mineral oil

    Drug: Placebo

  • Active comparator
    Topical Endoxifen 10mg/breast/day

    10 mg/day topical (Z)-endoxifen; Transcutol™ (2-(2-Ethoxyethoxy)ethanol); isopropanol, Crodamol™ GTCC (a fully saturated emollient triester) and mineral oil

    Drug: Topical endoxifen

  • Active comparator
    Topical Endoxifen 20mg/breast/day

    20 mg/day topical (Z)-endoxifen; Transcutol™ (2-(2-Ethoxyethoxy)ethanol); isopropanol, Crodamol™ GTCC (a fully saturated emollient triester) and mineral oil

    Drug: Topical endoxifen

Interventions

06

What researchers measure

Primary outcomes

  1. Change in Mammographic Breast Density At Study Exit

    Change, on an individual level, in mammographic breast density, measured at 6 months or when exiting from the study (baseline screening mammography)

    Time frame: From baseline to study exit up to 6 months

07

Results

Posted Jun 18, 2021
Limitations and caveats
Early discontinuation of subjects due to AEs related to skin reactions lead to small numbers of completed subjects and inability to analyze the primary endpoint as outlined in the protocol.

Participant flow

Participant flow — Overall Study
MilestoneControlTopical Endoxifen 10mg/Breast/DayTopical Endoxifen 20mg/Breast/Day
Started303030
Completed2320
Not completed72830

Outcome measures

PrimaryChange in Mammographic Breast Density At Study Exit

Change, on an individual level, in mammographic breast density, measured at 6 months or when exiting from the study (baseline screening mammography)

Time frame:
From baseline to study exit up to 6 months
Reported as:
Mean · percent change from baseline
Change in Mammographic Breast Density At Study Exit
percent change from baselineControlTopical Endoxifen 10mg/Breast/DayTopical Endoxifen 20mg/Breast/Day
Change in Mammographic Breast Density At Study Exit-1.85 ± 5.58-2.14 ± 6.50-3.75 ± 7.81

Adverse events

Collected over Up to 6 months. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Control0/30 (0%)0/30 (0%)27/30 (90%)
Topical Endoxifen 10mg/Breast/Day0/30 (0%)0/30 (0%)28/30 (93.3%)
Topical Endoxifen 20mg/Breast/Day0/30 (0%)0/30 (0%)27/30 (90%)
Most frequent other events
Showing 10 of 51
Most frequent other events
EventControlTopical Endoxifen 10mg/Breast/DayTopical Endoxifen 20mg/Breast/Day
Rashes on breast skinSkin and subcutaneous tissue disorders12/3021/3026/30
Sexual feeling decreasedPsychiatric disorders23/3019/3015/30
Itching from the breast skinGeneral disorders6/3021/3022/30
Dryness vaginalReproductive system and breast disorders22/3022/3013/30
Night sweatsReproductive system and breast disorders21/3013/3014/30
Menopausal hot flushesReproductive system and breast disorders19/3014/3016/30
Painful intercourseReproductive system and breast disorders19/3016/3014/30
Fragile mucous membranesGeneral disorders18/3014/3014/30
Muscle cramps (e.g. in legs)Musculoskeletal and connective tissue disorders18/3011/3011/30
HeadachesNervous system disorders17/3011/305/30

Baseline characteristics

Age, Continuous
Age, Continuous(years)ControlTopical Endoxifen 10mg/Breast/DayTopical Endoxifen 20mg/Breast/DayTotal
Mean54.9 ± 6.0156.9 ± 7.9757.7 ± 8.4156.5 ± 7.5
Sex: Female, Male
Sex: Female, Male(Participants)ControlTopical Endoxifen 10mg/Breast/DayTopical Endoxifen 20mg/Breast/DayTotal
Female30303090
Male0000
Race and Ethnicity Not Collected
Race and Ethnicity Not Collected(Participants)ControlTopical Endoxifen 10mg/Breast/DayTopical Endoxifen 20mg/Breast/DayTotal
Count of participants———0
Region of Enrollment
Region of Enrollment(Participants)ControlTopical Endoxifen 10mg/Breast/DayTopical Endoxifen 20mg/Breast/DayTotal
Sweden30303090
BMI
BMI(kg/m^2)ControlTopical Endoxifen 10mg/Breast/DayTopical Endoxifen 20mg/Breast/DayTotal
Mean24.9 ± 2.7725.6 ± 3.5725.2 ± 3.0825.2 ± 3.1
Blood pressure (systolic)
Blood pressure (systolic)(mm Hg)ControlTopical Endoxifen 10mg/Breast/DayTopical Endoxifen 20mg/Breast/DayTotal
Mean117.5 ± 12.1123.7 ± 8.45120.4 ± 10.1120.5 ± 10.5
Weight
Weight(kg)ControlTopical Endoxifen 10mg/Breast/DayTopical Endoxifen 20mg/Breast/DayTotal
Mean69.0 ± 7.3369.8 ± 9.7470.2 ± 9.3169.7 ± 8.8
Height
Height(cm)ControlTopical Endoxifen 10mg/Breast/DayTopical Endoxifen 20mg/Breast/DayTotal
Mean166.6 ± 5.14165.3 ± 6.38167.0 ± 6.06166.3 ± 5.9

2 further baseline measures are reported on the registry.

08

Study locations

1 site
  • Karolinska Institutet
    Stockholm, Sodersjukhuset, Sweden
09

References and documents

Publications

  • Backlund M, Eriksson M, Gabrielson M, Hammarstrom M, Quay S, Bergqvist J, Hellgren R, Czene K, Hall P. Topical Endoxifen for Mammographic Density Reduction-A Randomized Controlled Trial. Oncologist. 2022 Jul 5;27(7):e597-e600. doi: 10.1093/oncolo/oyac102. PubMed 35604960 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Apr 2018 to primary completion in Sep 2018, 5 months.

Results were first posted in Jun 2021, 2 years 9 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 16, 2020
First posted
Nov 5, 2020
StartActual
Apr 9, 2018
Primary completionActual
Sep 10, 2018
CompletionActual
Sep 4, 2019
Results first posted
Jun 18, 2021
Last update
Jul 12, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 12, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04616430
Lead sponsor
Atossa Therapeutics, Inc.
Responsible party
Sponsor
First posted
Nov 5, 2020
Start date
Apr 9, 2018
Primary completion
Sep 10, 2018
Completion
Sep 4, 2019
Results posted
Jun 18, 2021
Last update
Jul 12, 2021

Study contacts

Per Hall, MD
principal investigator · Karolinska Institutet

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Endoxifen

Start the discussion